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summary
The interferon (IFN) signature, namely the overexpression of IFN-inducible genes is a crucial aspect in the 
pathogenesis of primary Sjögren’s syndrome (pSS). The IFN-inducible IFI16 protein, normally expressed in 
cell nuclei, may be overexpressed, mislocalized in the cytoplasm and secreted in the extracellular milieu in sev-
eral autoimmune disorders including pSS. This leads to tolerance breaking to this self-protein and development 
of anti-IFI16 antibodies. The aim of this study was to identify pathogenic and clinical significance of IFI16 and 
anti-IFI16 autoantibodies in pSS.
IFI16 and anti-IFI16 were assessed in the serum of 30 pSS patients and one-hundred healthy donors (HD) by 
ELISA. IFI16 was also evaluated in 5 minor salivary glands (MSGs) of pSS patients and 5 MSGs of non-pSS 
patients with sicca symptoms by immunohistochemistry.
Normal MSGs do not constitutively express IFI16. Conversely, in pSS-MSGs a marked expression and cyto-
plasmic mislocalization of IFI16 by epithelial cells was observed with infiltrations in lymphocytes and peri/
intra-lesional endothelium. pSS patients display higher serum levels of both IFI16 and anti-IFI16 autoantibod-
ies compared to HD. 
Our data suggest that IFI16 protein may be involved in the initiation and perpetuation of glandular inflammation 
occurring in pSS. 
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n	 INTRODUCTION
Primary Sjögren’s syndrome (pSS) is a chronic autoimmune disorder mainly 
affecting exocrine glands. The clinical 
spectrum of pSS ranges from mild symp-
toms of mucosal dryness to severe extrag-
landular manifestations. Non-Hodgkin’s 
lymphoma is the most severe complication 
(1). The histological hallmark of pSS is a 
periductal/perivascular mononuclear cell 
infiltrate of at least 50 lymphocytes (focus). 
Although the pathogenesis of pSS is not en-
tirely clarified, growing evidence points to 
the central role of interferon (IFNs) in the 
initiation and perpetuation of the disease 
(2, 3). Type I IFNs are early mediators of 
the innate immune response that foster the 
adaptive immune response through direct 
and indirect effects on dendritic cells, T and 
B cells, and natural killer cells. Increased 
expression of IFN-inducible genes, namely 
the type I IFN signature, has been reported 
in systemic lupus erythematosus, systemic 
sclerosis (SSc), rheumatoid arthritis and 
pSS (4-7). Among IFN-inducible genes, 
the interferon gamma-inducible protein 16 
(IFI16), a member of the HIN200/Ifi200 
family has been recently investigated in 
several autoimmune diseases including 
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pSS (8-12). IFI16 is normally expressed 
in cell nuclei of hematopoietic cells, par-
ticularly lymphocytes, vascular endothelial 
cells and keratinocytes (13). 
IFI16 aberrant overexpression drives early 
steps of the inflammatory response through 
nuclear factor kappa B mediated secretion 
of proinflammatory molecules such as in-
tercellular adhesion molecule 1, E-selectin, 
interleukin-8 and monocyte chemoattrac-
tant protein-1 (12, 14, 15). It is worth not-
ing that an overexpression and mislocal-
ization in the cytoplasm was described in 
target organs of autoimmune diseases, such 
as the skin in SSc (16). 
IFI16 is also increased in serum samples 
of patients with autoimmune diseases (8-
12). Such events, namely the extracellular 
spreading of IFI16, lead to the breaking of 
tolerance to this self-protein and eventually 
to the development of anti-IFI16 autoanti-
bodies (17). 
On this basis, it is reasonable to speculate 
that IFI16 may act as an autoantigen in pSS 
and therefore be involved in the develop-
ment of autoimmunity (14). The aim of this 
study was to investigate possible pathogen-
ic, diagnostic and prognostic significance 
of IFI16 protein and anti-IFI16 autoanti-
bodies in patients with pSS.
n	 MATERIALS AND METHODS
Patients
Thirty consecutive patients with pSS, clas-
sified according to the European-American 
criteria (18), were enrolled. One-hundred 
sex- and age-matched healthy donors (HD) 
were selected as controls. Five pSS minor 
salivary glands (MSGs), collected at the 
time of diagnosis, were also retrospective-
ly evaluated. Five normal MSGs obtained 
from subjects with sicca symptoms, but 
without any clinical and serological fea-
tures of pSS, were used as controls. The 
whole study was approved by the local Eth-
ics Committee and written informed con-
sent was obtained in accordance with the 
declaration of Helsinki.
Determination of extracellular IFI16 
protein by capture ELISA
A capture ELISA was used to measure the 
circulating extracellular IFI16 protein with 
a procedure described below (10).
Determination of antibody titres towards 
human recombinant IFI16 by ELISA
To detect anti-IFI16 antibodies, polysty-
rene micro-well plates (Nunc-Immuno 
MaxiSorp; Nunc, Roskilde, Denmark) 
Figure 1 -  expression of iFi16 protein (a) and anti-iFi16 antibodies (B) in healthy donors (HD) 
(n. 100) and primary Sjögren’s syndrome (pSS) patients (n. 30). Dotted lines mark cut-off levels 
of positivity as determined as the 95th percentile of the control population. p values were cal-
culated with Mann Whitney U test.
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were coated with a solution of recombinant 
IFI16 in phosphate-buffered saline and, af-
ter blocking, sera were added in duplicate, 
as previously described (11, 12).
Histological analysis of minor salivary 
glands biopsies
Labial MSG specimens were scored using 
hematoxilin-eosin staining sections (focus 
score, number of foci in 4 mm2 of tissue) 
(19, 20).
IFI16 expression was evaluated using stan-
dard immunohistochemistry, as already 
described in a previous study (17). Images 
were acquired using an Olympus BX53 
fluorescence microscope with CellSens 
software (Olympus America Inc., Center 
Valley, PA, USA). 
Statistical analysis
Data analysis was performed using Graph-
Pad 5.0 software. Mann Whitney U test or 
Chi square test were used to compare vari-
ables among subgroups. The significance 
level was two sided and set at p<0.05.
n	 RESULTS
Serum IFI16 protein and anti-IFI16 
antibody are highly expressed in primary 
Sjögren’s syndrome
Cut-off values were established according 
to the 95th percentile of the control popu-
lation, being 27 ng/mL and 113 U/mL for 
IFI16 protein and anti-IFI16 autoantibod-
ies, respectively. 
As shown in Figure 1A and B, serum lev-
els of both IFI16 protein and anti-IFI16 
autoantibodies were higher in pSS than in 
HD (p<0.01 and p<0.0001, respectively). 
IFI16 was significantly more prevalent in 
pSS compared to HD as it was detectable 
in 6/30 patients (21%) and in 5/100 (5%) 
(p<0.05). Similarly, a significantly higher 
prevalence in pSS was confirmed also for 
anti-IFI16 antibodies that were present in 
10/30 pSS patients (33%) and in 5/100 HD 
(5%) (p<0.001).
Table I summarizes clinical and serological 
features in pSS patients. We failed to ob-
serve any clinical or serological differences 
according to the positivity/concentration of 
Table I - Clinical and serological features of patient 
cohort.
number of patients 30
Female 30 (100%)
age (mean ± SeM) 58±2,3
age at diagnosis  
(mean ± SeM)
49±2,4
Disease duration 
(mean ± SeM)
8,8±1
Xerostomia 28 (93)
Xerophtalmia 28 (93)
Salivary swelling 17 (57)
articular involvement 18 (60)
purpura 2 (7)
raynaud’s phenomenon 3 (10)
Visceral involvement 8 (27)
lymphadenopathy 2 (7)
lymphoma 1 (3)
Hypocomplementemia 7 (23)
leukopenia 14 (47)
Hypergammaglobulinemia 17 (57)
Monoclonal component 3 (10)
autoantibodies
neither anti-SSa nor anti-SSB 4 (13)
anti-SSa only 9 (30)
Both anti-SSa and anti-SSB 17 (57)
rheumatoid factor 22 (73)
Cryoglobulins 1 (3)
Topical drugs 23 (77)
Hydroxicloroquine 16 (53)
Methotrexate 6 (20)
Unless specified, values are displayed as number 
of patients (percentage). SeM, standard error of 
the mean. 
IFI16 or positivity/titer of antiIFI16 auto-
antibodies. 
IFI16 protein is highly expressed and 
mislocalized in the cytoplasm at glandular 
level in primary Sjögren’s syndrome
Figure 2A and B display a representative 
normal and pSS MSG stained with hema-
toxilin and eosin. The histological analysis 
of normal MSGs revealed that IFI16 pro-
tein was not constitutively expressed by the 
glandular tissue (Fig. 2C). Conversely, in 
pSS biopsies IFI16 was highly expressed 
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in the nuclei of both ductal and acinar epi-
thelial cells. It is worth noting that IFI16 
is aberrantly expressed in the cytoplasm of 
ductal epithelial cells (Figure 2D). IFI16 
nuclear and cytoplasmic staining was also 
observed in the inflammatory cells infiltrat-
ing the tissue (Fig. 2D). Finally, the consti-
tutional expression of IFI16 in the nuclei 
of endothelial cells that could be detected 
in normal MSGs was more pronounced in 
pSS peri- and intra-lesional endothelium 
(Fig. 2C-D, inserts).
n	 DISCUSSION AND 
 CONCLUSIONS
A large body of evidence supports the 
pathogenic role of the IFN signature in 
several autoimmune diseases including 
pSS (6, 21). However several aspects of this 
pathway as well as the role of each IFN-
inducible molecule are not fully elucidated.
Our study demonstrated that the IFN induc-
ible protein IFI16 is aberrantly expressed in 
sera and target organs of patients with pSS. 
In addition we confirmed that pSS patients 
display circulating autoantibodies towards 
IFI16. Therefore, it is reasonable to postu-
late that IFI16 protein may be involved in 
the induction and maintenance of glandu-
lar inflammation and, more generally, in 
triggering the autoimmune response.
Previous studies pointed out that IFI16 is 
involved in the regulation of cell growth, 
differentiation, and angiogenesis. In fact, 
its overexpression leads to decreased cell 
proliferation with a block in the cell cycle 
progression at the G1-S phase transition of 
cancer cell lines, and to an impairment of 
tube morphogenesis and proliferation of 
human endothelial cells (22, 23). IFI16 is 
expressed in myeloid precursor cells and 
such expression remains stable throughout 
the lymphoid development. In addition, 
the histological evaluation of a variety of 
normal tissues revealed that IFI16 expres-
sion is highly clustered. As far as epithelial 
cells are concerned, IFI16 expression was 
described in skin, gastrointestinal tract, 
urogenital tract, and glands and ducts of 
breast tissues (13, 24). This tissue-specific 
physiological expression of IFI16 may in-
dicate that this molecule is involved in the 
early phases of inflammation.
In this study we demonstrated that, un-
like other epithelial cells, those of normal 
MSGs do not constitutively express IFI16 
protein. Conversely, a marked expression 
of this molecule by acinar and ductal epi-
thelial cells as well as infiltrating lympho-
cytes and peri/intra-lesional endothelium 
could be observed during pSS. Hence, 
IFI16 expression appears to be induced de 
novo in the target tissue of this disease.
Recently, it has been hypothesized that 
salivary gland epithelial cells are actively 
involved in the initiation and perpetuation 
of pSS (25) and IFN appears to be crucial 
in this scenario. In fact, IFN binding to 
toll-like receptors aberrantly expressed by 
activated salivary gland epithelium leads to 
an up-regulation and mislocalization in the 
cytoplasm of nuclear proteins. Besides the 
well-known Ro52 and Ro60 nuclear pro-
teins, our findings suggest that also IFI16 
may undergo this fate in pSS-MSGs. In de-
Figure 2 - expression of iFi16 in minor sa-
livary glands (MSgs). Hematoxilin and eo-
sin staining of normal MSg (a) and primary 
Sjögren’s syndrome (pSS) MSg (B). immu-
nohistochemical analysis for iFi16 in normal 
MSg (C) and pSS-MSg (D). inserts in C and 
D depict a detail of endothelial cells from the 
corresponding panel.
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tail, IFN over-expression occurring early 
in the disease may induce salivary epithe-
lial cells to express IFI16, which is normal-
ly absent in these cells, to upregulate it at 
pathological levels and to miscolocalize it 
in the cytoplasm.
The abnormal release in the extracellular 
milieu of nuclear proteins normally hidden 
to the immune system, including IFI16, 
leads to tolerance breaking, antigen-specif-
ic B-cell activation and, eventually, auto-
antibody production. IFI16, therefore, may 
act as an autoantigen in pSS being involved 
in the disease pathogenesis. In addition the 
evidence that IFI16 is also overexpressed 
and mislocalized in the cytoplasm of in-
filtrating lymphocytes further underscores 
its possible pathogenic role. Finally, the 
consistent presence of IFI16 in pSS peri/
intra-lesional endothelial cells fits with the 
recent observation that IFI16 overexpres-
sion in endothelial cells in another pebble 
in the mosaic of inflammation (14, 15). 
The aforementioned observation, together 
with the evidence that only a subgroup of 
pSS patients display consistent levels of 
circulating IFI16, allow us to speculate 
that the main pathogenic role of IFI16 is 
exerted at glandular tissue level. Similarly, 
since IFI16 may exert its role of autoanti-
gen mainly at tissue level, again only a sub-
group of patients display circulating anti-
IFI16 autoantibodies.
In conclusion, our study provides some 
bases to understand the pathogenic role of 
IFI16 and anti-IFI16 autoantibodies in pSS. 
Larger and prospective studies are required 
to identify the potential diagnostic and/or 
prognostic role of IFI16 protein anti-IFI16 
autoantibodies in pSS and eventually pro-
vide the rationale for their detection in 
clinical practice.
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